150 related articles for article (PubMed ID: 19914686)
21. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
Haraoui B
J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
[No Abstract] [Full Text] [Related]
22. Anti-cytokine antibodies for rheumatic diseases.
Atzeni F; Sarzi-Puttini P
Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
[TBL] [Abstract][Full Text] [Related]
23. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
24. [Pregnancy in rheumatic patients treated with biologic drugs].
Sentić M; Baresić M; Anić B; Bosnić D; Cerovec M; Mayer M; Smiljanić L; Cikes N
Lijec Vjesn; 2010; 132(9-10):317-8. PubMed ID: 21261033
[No Abstract] [Full Text] [Related]
25. [Biological treatment of rheumatic diseases].
Procházková L; Böhmová J; Soucek M
Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
[TBL] [Abstract][Full Text] [Related]
26. Mycobacterial disease in patients with rheumatic disease.
van Ingen J; Boeree MJ; Dekhuijzen PN; van Soolingen D
Nat Clin Pract Rheumatol; 2008 Dec; 4(12):649-56. PubMed ID: 19037226
[TBL] [Abstract][Full Text] [Related]
27. [Biological treatment of rhematoid diseases].
Pavelka K
Vnitr Lek; 2006 Jun; 52(6):561-2. PubMed ID: 16871758
[No Abstract] [Full Text] [Related]
28. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
Yelin E; Katz P
Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
[No Abstract] [Full Text] [Related]
29. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.
Zingarelli S; Frassi M; Bazzani C; Scarsi M; Puoti M; Airò P
J Rheumatol; 2009 Jun; 36(6):1188-94. PubMed ID: 19447932
[TBL] [Abstract][Full Text] [Related]
30. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.
Calabrese LH; Zein N; Vassilopoulos D
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii18-ii24. PubMed ID: 15479865
[TBL] [Abstract][Full Text] [Related]
31. Advances in targeted therapies X. Preface.
Breedveld FC; Kalden JR; Smolen JS
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii1. PubMed ID: 19022807
[No Abstract] [Full Text] [Related]
32. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.
Ramos-Casals M; Perez-Alvarez R; Perez-de-Lis M; Xaubet A; Bosch X;
Am J Med; 2011 May; 124(5):386-94. PubMed ID: 21531225
[TBL] [Abstract][Full Text] [Related]
34. Adverse effects of golimumab in the treatment of rheumatologic diseases.
Yang H; Kavanaugh A
Expert Opin Drug Saf; 2014 Jan; 13(1):103-12. PubMed ID: 23984970
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumour necrosis factor agents and lipid profile: a class effect?
Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
[No Abstract] [Full Text] [Related]
36. Tumor necrosis factor alpha inhibitors and methotrexate: implications for deployed personnel.
Martin JJ
Aviat Space Environ Med; 2005 Dec; 76(12):1162-6. PubMed ID: 16370267
[TBL] [Abstract][Full Text] [Related]
37. [TNF-alpha antagonists in therapy of rheumatoid arthritis].
Gross WL; Gause A
Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691
[No Abstract] [Full Text] [Related]
38. [Serious lung disease in RA and TNF-blockade--is there a connection?].
Turesson C; Jacobsson L; Saxne T; Geborek P
Lakartidningen; 2006 Feb 1-7; 103(5):308; author reply 308-9. PubMed ID: 16512575
[No Abstract] [Full Text] [Related]
39. [Do DMARDs contibute to impaired healing after surgery? Should they be discontinued before surgery?].
Glück T; Müller-Ladner U
Dtsch Med Wochenschr; 2007 Sep; 132(37):1901-4. PubMed ID: 17823884
[No Abstract] [Full Text] [Related]
40. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
Curtis JR; Martin C; Saag KG; Patkar NM; Kramer J; Shatin D; Allison J; Braun MM
Arthritis Rheum; 2007 Mar; 57(2):343-6. PubMed ID: 17330283
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
